Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Share-based Payment Arrangement [Abstract]

Schedule of non-cash share-based compensation expense

Non-cash share-based compensation expense, consisting of expense for stock options, Restricted Share Units ("RSUs"), Performance Share Units ("PSU"), and Employee Share Purchase Plan ("ESPP"), was classified in the condensed

consolidated statements of operations and comprehensive loss as follows:

	Three months ended March 31,
	2022		2021
Research and development expenses	$	33,953	$	20,058
Selling, general and administrative expenses	47,875		28,668
Total non-cash share-based compensation expense	$	81,828	$	48,726
Less: Share-based compensation expense attributable to non-controlling interests	498		360
Share-based compensation expense attributable to Biohaven Pharmaceutical Holding Company Ltd.	$	81,330	$	48,366

Schedule of stock option activity

The following table is a summary of the Company's stock option activity for the three months ended March 31, 2022:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding as of December 31, 2021	7,089,727	$40.15
Granted	1,243,000	$128.09
Exercised	(46,665)	$60.06
Forfeited	(3,750)	$63.01
Outstanding as of March 31, 2022	8,282,312	$53.22	7.01	$	553,426
Options exercisable as of March 31, 2022	5,689,393	$38.82	6.31	$	456,699
Vested and expected to vest as of March 31, 2022	8,282,312	$53.22	7.01	$	553,426

Schedule of RSU activity

The following table is a summary of the RSU and PSU activity for the three months ended March 31, 2022:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested as of December 31, 2021	1,218,070	$78.98
Granted	1,064,917	$127.95
Forfeited	(14,085)	$97.19
Vested	(561,296)	$94.12
Unvested as of March 31, 2022	1,707,606	$104.39